Otsuka Holdings Co., Ltd. Logo

Otsuka Holdings Co., Ltd.

A global healthcare company with pharmaceutical and nutraceutical businesses.

4578 | T

Overview

Corporate Details

ISIN(s):
JP3188220002
LEI:
Country:
Japan
Address:
千代田区神田司町2−9

Description

Otsuka Holdings Co., Ltd. is a global healthcare company dedicated to creating innovative products for better health worldwide. The company operates through two core segments: a Pharmaceutical business and a Nutraceutical business. The Pharmaceutical division focuses on the research, development, and commercialization of treatments for diseases, with key areas including central nervous system disorders, oncology, cardiovascular diseases, and infectious diseases. The Nutraceutical division provides products based on scientific evidence to support daily health maintenance and improvement. This segment includes a wide range of functional foods, nutritional supplements, functional beverages, and cosmeceuticals, with well-known brands such as POCARI SWEAT, Calorie Mate, and Nature Made.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2024-03-29 08:08
内部統制報告書-第16期(2023/01/01-2023/12/31)
Japanese 23.9 KB
2024-03-29 08:07
有価証券報告書-第16期(2023/01/01-2023/12/31)
Japanese 4.4 MB
2024-03-28 08:12
臨時報告書
Japanese 41.0 KB
2024-01-04 08:17
臨時報告書
Japanese 20.5 KB
2023-10-31 08:12
四半期報告書-第16期第3四半期(2023/07/01-2023/09/30)
Japanese 357.5 KB
2023-10-31 08:12
確認書
Japanese 8.3 KB
2023-07-31 09:13
確認書
Japanese 8.3 KB
2023-07-31 09:12
四半期報告書-第16期第2四半期(2023/04/01-2023/06/30)
Japanese 359.9 KB
2023-05-12 09:09
確認書
Japanese 8.3 KB
2023-05-12 09:08
四半期報告書-第16期第1四半期(2023/01/01-2023/03/31)
Japanese 296.1 KB
2023-03-31 09:15
確認書
Japanese 8.3 KB
2023-03-31 09:14
内部統制報告書-第15期(2022/01/01-2022/12/31)
Japanese 23.9 KB
2023-03-31 09:13
有価証券報告書-第15期(2022/01/01-2022/12/31)
Japanese 2.0 MB
2022-11-02 08:07
四半期報告書-第15期第3四半期(令和4年7月1日-令和4年9月30日)
Japanese 352.7 KB
2022-11-02 08:07
確認書
Japanese 8.4 KB

Automate Your Workflow. Get a real-time feed of all Otsuka Holdings Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Otsuka Holdings Co., Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Otsuka Holdings Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.